Potential drug interactions and chemotoxicity in older patients with cancer receiving chemotherapy
Introduction
Increasing age and polypharmacy are associated for a number of reasons. These include: increased prevalence of multimorbidity;[1], [2], [3], [4], [5], [6] absence of a primary care provider able to coordinate the care of different specialists;[7], [8] and increased use of alternative forms of treatments.9 Also older individuals may keep taking medications they no longer need when multiple physicians and multiple sites of care are involved.8
Information related to polypharmacy in older patients with cancer is limited.10 Six studies[5], [11], [12], [13], [14], [15] were conducted in ambulatory and three[16], [17], [18] in hospitalized patients with cancer. All studies revealed high prevalence of polypharmacy, and its associated risk of drug interactions. The risk of interaction ranged from 29 to 58%,[13], [15], [16] and in two studies[16], [17] the risk of inappropriate prescriptions varied between 29 and 41%. None of the studies assessed the clinical consequences of polypharmacy. In our program, older patients take an average of 6 medications, 2 of them being metabolized by p450, a key player (although not the only one) in drug interactions.19
In the present study we investigated the prevalence and severity of drug–drug interactions in older patients with cancer receiving chemotherapy, the association between drug interactions and chemotherapy-related toxicity, and the correlation between the risk of drug-drug interactions and the number of medications taken by each patient. The Senior Adult Oncology Program (SAOP) at the Moffitt Cancer Center in Tampa represents a suitable setting for this research. Established in 1993 for the management of patients with cancer aged 70 and over, the SAOP collects comprehensive baseline information, including a geriatric screening and a record of all medications the patients take at initial presentation, using self reports, brown bag approach, and previous medical records. It updates the medication list at each subsequent visit.
Section snippets
Study Design and Participants
This is a retrospective medical record review of patients with cancer aged ≥ 70 years who received chemotherapy in the SAOP in 1995–2005. This study was approved by the Institutional Review Board at the University of South Florida. It uses a cohort that we created to study the impact of p450 interactions on tolerance of chemotherapy in the elderly.19 We reviewed the records of all patients who received regimens including at least one chemotherapeutic agent metabolized by the cytochrome p450 (CYP)
Epidemiology
The sample characteristics are presented in Table 2. Sixty-six patients (27%) experienced a G4 hematological toxicity; 126 patients (51.6%) experienced grades 3–4 non-hematological toxicity; among them, 40 (16.4%) experienced both types of toxicity.
At the time of chemotherapy initiation, patients in our sample reported taking a mean of 11.7 ± 4.6 drugs (range 3–41), including prescription chemotherapy and non-chemotherapy drugs, over the counter drugs, herbals, and supplements. We identified 769
Prevalence
Our study confirms the high number of medications taken by patients with cancer, with the resulting PDI, and provides data more specific to patients above the age of 70. This is the first study to establish the incidence and severity of PDIs and their association with severe chemotherapy adverse events in these patients.
In comparison with studies in general outpatient oncologic populations, our proportion of patients presenting PDIs is higher: Riechelmann et al. report a proportion of 27%, and
Conclusions
In conclusion, in a sample of cancer patients aged ≥ 70 years we found notable rates of PDI and a substantial association between high-level PDI and risk of non-hematological toxicity from chemotherapy. This is a call for oncologists to carefully review and trim down the list of medications of their older patients before initiating chemotherapy. The electronization of medical records and prescribing offers opportunities for an integrated use of drug interaction software. Since not all PDIs can be
Disclosures and Conflict of Interest Statements
Dr. Popa is presently employed by Biovest International (this company has no relationships with the software used in this article). Dr. Extermann has research funding from Gtx and Dr. Balducci has honoraria from AMGEN, TEVA and Janssen. Drs. Wallace and Brunello have nothing to disclose. The work was supported in part by NIH funds.
Author Contributions
Study concept and design: M.A. Popa, M. Extermann, L. Balducci
Data acquisition: M.A. Popa, A. Brunello
Data analysis and interpretation: M.A. Popa, K. Wallace, M. Extermann, L. Balducci
Manuscript preparation: M.A. Popa, M. Extermann, L. Balducci
Manuscript editing and review: M.A. Popa, K. Wallace, A. Brunello, M. Extermann, L. Balducci
References (64)
- et al.
Comorbidity and geriatric assessment for older patients with hematologic malignancies: a review of the evidence
J Geriatr Oncol
(2012) - et al.
Polypharmacy and drug use in elderly Danish cancer patients during 1996 to 2006
J Geriatr Oncol
(2012) - et al.
Knowledge of prescription medications among cancer patients aged 65 years and above
J Geriatr Oncol
(2012) - et al.
Polypharmacy and the management of the older cancer patient
Ann Oncol
(2013) - et al.
Patient characteristics associated with polypharmacy and inappropriate prescribing of medications among older adults with cancer
J Geriatr Oncol
(2012) - et al.
Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method
Ann Oncol
(2011) - et al.
Potential drug interactions in cancer patients receiving supportive care exclusively
J Pain Symptom Manage
(2008) - et al.
Polypharmacy in hospitalized older adult cancer patients: experience from a prospective, observational study of an oncology — acute care for elders unit
Am J Geriatr Pharmacother
(2009) - et al.
Predictors of tolerance to chemotherapy in older cancer patients: a prospective pilot study
Eur J Cancer
(2002) - et al.
Predictors of treatment failures during chemotherapy: a prospective study on 110 older cancer patients
Arch Gerontol Geriatr
(2009)
MAX2 — a convenient index to estimate the average per patient risk for chemotherapy toxicity; validation in ECOG trials
Eur J Cancer
A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy
Am J Med
Effects of geriatric evaluation and management on adverse drug reactions and suboptimal prescribing in the frail elderly
Am J Med
Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients
Gynecol Oncol
Cyclophosphamide metabolism is affected by azole antifungals
Blood
Drug interactions in oncology
Lancet Oncol
Acute renal failure due to concomitant action of methotrexate and indomethacin
Lancet
A patient with a prolonged prothrombin time due to an adverse interaction between 5-fluorouracil and warfarin
Am J Gastroenterol
Decreased phenytoin level after carboplatin treatment
Am J Med
Clinically significant drug–drug interactions between oral anticancer agents and nonanticancer agents: a Delphi survey of oncology pharmacists
Clin Ther
Integrating a geriatric evaluation in the clinical setting
Semin Radiat Oncol
Predictive value of geriatric assessment for patients older than 70 years, treated with chemotherapy
Crit Rev Oncol Hematol
Potentially harmful drug–drug interactions in the elderly: a review
Am J Geriatr Pharmacother
Fatal interaction between methotrexate and naproxen
Lancet
Drug interactions between chemotherapeutic regimens and antiepileptics
Clin Ther
Patterns of multimorbidity in elderly veterans
J Am Geriatr Soc
Exposure to potentially harmful drug-disease interactions in older community-dwelling veterans based on the Healthcare Effectiveness Data and Information Set quality measure: who is at risk?
J Am Geriatr Soc
Impact of age and comorbidity on colorectal cancer screening among older veterans
Ann Intern Med
Fragmentation of care for frail older people — an international problem. Experience from three countries: Israel, Canada, and the United States
J Am Geriatr Soc
Managing medications in clinically complex elders: “There's got to be a happy medium”
JAMA
Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States
JAMA
Use of prescription and nonprescription medications and supplements by cancer patients during chemotherapy: questionnaire validation
J Oncol Pharm Pract
Cited by (91)
Decreasing polypharmacy in older adults with cancer: A pilot cluster-randomized trial protocol
2024, Journal of Geriatric OncologyA systematic scoping review of interventions to optimise medication prescribing and adherence in older adults with cancer
2022, Research in Social and Administrative PharmacyResearch priorities to address polypharmacy in older adults with cancer
2021, Journal of Geriatric OncologyCitation Excerpt :In regards to drug-drug interactions, significant variability of evidence exists. This variability is likely related to inconsistent study designs and methodologies used for screening/assessing potential interactions (e.g., clinician-led assessment, clinical decision support software) and to heterogeneity across study populations [24–27]. Research should explore how best to define drug-drug interactions (e.g., moderate, major, clinically significant), including optimal screening tools based on healthcare settings, cancer types, and cancer stages.
Role of the Pharmacist in the Management of Polypharmacy and Drug Interactions in the Elderly Patient with Chemotherapy
2024, Current Cancer Therapy Reviews